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Radiopharmacokinetics and uptake of 99mTc-cRGD in
v3 integrins for imaging angiogenesis in induced
malignant tumors in athymic mice
Fred A. López-Durán,* Martha Pedraza-López,** Consuelo Arteaga de Murphy,** Edith
Hernández-Hernández,*** Rocío García-Becerra,**** David Ordaz-Rosado****
RESUMEN
Los receptores de integrinas v 3 se encuentran en la pared
endotelial de los vasos sanguíneos y están sobreexpresados,
sobre todo en los nuevos vasos de los tumores malignos.
Para visualizar la neoangiogénesis en tumores inducidos con
células cancerosas de páncreas, mama y próstata en ratones
atímicos se desarrolló un nuevo radiofármaco de tecnecio-
99m (99mTc). El péptido cíclico con los aminoácidos: -Arg-Gly-
Asp-D-Phe-Lys- se marcó con 99mTc por medio del ligante bi-
funcional ácido hidracinonicotínico (HYNIC) y del coligante
etilendiaminodiacético (EDDA). El 99mTc-EDDA/HYNIC-
cyclic-Arg-Gly-Asp-D-Phe-Lys (99mTc-cRGD) con pureza ra-
dioquímica > 95%, se une in vivo a los receptores de integri-
nas v 3 con alta especificidad. En los ratones atímicos con
cáncer inducido presenta rápida depuración sanguínea y eli-
minación renal y hay diferencias estadísticamente significati-
vas entre la captación del tumor comparada contra la capta-
ción en músculo, en los tres tipos de neoplasias. La relación
más alta tumor/músculo fue de 7.2 a las 24 h para el cáncer
de mama y se visualizó la neoangiogénesis en este tumor. La
alta resolución de la imagen demuestra que en la medicina
nuclear el 99mTc-cRGD será de gran valor como un radiofár-
maco que se une específicamente a receptores de integrinas v
3 y por consiguiente permite obtener imágenes moleculares
de tumores malignos con alta resolución.
Palabras clave: Péptido -RGD-99mTc, integrina v 3, ima-
gen molecular, angiogénesis.
ABSTRACT
The multistep process of angiogenesis offers several tar-
gets for therapeutic interventions. One molecular target
structure is the alfa five beta three (v 3 ) integrin which
is expressed on vascular endothelial cells and over-ex-
pressed in cancer tumor angiogenesis. To image neoangio-
genesis in athymic mice with induced pancreatic, breast
and prostate malignant tumors a new radiopharmaceuti-
cal was developed. The 99mTc-EDDA/HYNIC-cyclic-Arg-Gly-
Asp-D-Phe-Lys (99mTc-cRGD) targets integrin receptors v 3
and was prepared with an average radiochemical purity >
95 %. 99mTc-cRGD shows high in vivo stability, fast blood
clearance and rapid renal excretion in mice. There are sta-
tistical differences between tumor/muscle ratios for the 3
tumors studied. The highest tumor/non-target ratio was
found in breast cancer (7.2 after 24 h) and a representative
dorsal SPECT image was obtained where the tumor
showed up very clearly over the background tissue. The
high resolution of the image implies that 99mTc-cRGD will
be of great value in nuclear medicine as a potential radiop-
harmaceutical for v 3 integrins receptor uptake and for
imaging neoangiogenesis in neoplastic tissue and to fol-
low up cancer tumor progression.
Key words: Radiolabelled RGD-peptide, integrin v 3, mo-
lecular imaging, angiogenesis.
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INTRODUCTION
Angiogenesis is a complex natural physiologic pro-
cess that results in the formation of new vessels in a
tissue and during angiogenesis a group of cell mem-
brane receptors (transmembrane heterodimeric glu-
coproteins), called integrins modulate cell migration,
cell-cell interactions and cell binding to the extracel-
lular matrix.1-3
Angiogenesis is increased in several pathologic en-
tities including cancer. The integrins enhance vascu-
lar and lymphatic permeability and are directly in-
volved in cancer tumor-induced angiogenesis.2,4
Several studies have shown that there is a correla-
tion between v 3 receptor expression, angiogenesis
and the metastatic potential of the corresponding
cancer tumor.5
The multistep process of angiogenesis offers several
targets for therapeutic interventions. One target struc-
ture is the v 3 integrin, which is overexpressed
 in vas-
cular endothelial cells, and recognizes certain specific
amino acid sequences.4,6 It is of interest to study the de-
velopment of targeting radiopharmaceuticals for v 3
integrin receptors that could serve as antiangiogenic
therapeutics.7 Radiolabeled peptides containing the spe-
cific amino acid sequence —arginine-glycine-aspartic
acid— (RGD) have been used for targeting v 3 integrin
receptors and thus imaging angiogenesis.
RGD peptides have been labeled with 99mTc, 111In,
90Y, 123I, 64Cu, 68Ga. and 18F.8-12 There is especial inte-
rest in positron emitters for PET (positron emission
tomography) integrin v 3 expression imaging in can-
cer tumors. It was shown that constraining the mo-
bility of the linear RDG, by forming a cyclic peptide,
increased their integrin receptor affinity in vitro.13
Tetramer and octamer RDG peptides have been la-
beled with copper-64 for PET imaging of induced
glioblastomas in a mice model.14 Gallium-68 was
conjugated to cyclic RGDs through a macrocyclic che-
lator.11,12 For 18F labeling chemistry many linkers
and conjugated molecules in cyclic, monomeric and
polymeric structures have been used for PET. Some
radiopharmaceuticals are: 18F-galacto-RGD, the
dimeric cyclic 18F-E[c(RGDyK)]2 and the 18F-bombes-
in heterodimer. The tetrameric fluorinated aldehydes
that were conjugated to an amino-oxy-bearing RGD
peptide and linked to a polyethyleneglycol prosthetic
group gave the best biodistribution in mice.15-19 Nev-
ertheless 99mTc labeling is still the best option for in
situ radiopharmaceutical preparations useful for the
hybrid SPECT/CT (single-photon emission computed
tomography/computed tomography).20
A considerable number of synthetic peptides
modified from the five amino acid parent or
lead structure arginine-glycine-aspartic acid-
phenilalanine-valine amino acids (RGDfV) have
been assayed. Kok et al. reported that substitut-
ing the valine of the parental cRGDfV peptide
for a lysine amino acid shows high affinity for
v 3 integrins.
7 The cyclized-Arg-Gly-Asp-D-Phe-
Lys (cRGDfK), as a monomer or dimer, can be
technetium-99m labeled for targeting v 3 recep-
tors. The lysine side chain provides primary
amine functionality for coupling bifunctional
chelating agents such as hydrazinonicotinic acid
(HYNIC).3,21-23
Decristoforo et al. described the radiolabeling of a
HYNIC-derivatized cyclic monomeric RGD peptide con-
taining tyrosine and lysine amino acids [c(RGDyK
(HYNIC)] using tricine and ethylendiaminodiacetic
acid (EDDA) as coligands.24
The aim of this research was to easily prepare a
99mTc-EDDA/HYNIC-cyclic-Arg-Gly-Asp-D-Phe-Lys
(99mTc-cRGD) radiopharmaceutical, to determine its
biopharmacokinetics, estimate v 3 integrin receptor
uptake and to image angiogenesis in athymic mice
with induced malignant pancreatic, breast and pros-
tate tumors.
METHODS
Preparation of 99mTc-EDDA/HYNIC-cyclic-Arg-
Gly-Asp-D-Phe-Lys (99mTc-cRGD)
The cyclic-Arg-Gly-Asp-D-Phe-Lys pentapeptide
(cRGD) (Bachem, USA) was conjugated to hydrazi-
nonicotinic acid (HYNIC) via o-(7-azabenzotria-
zolyl)-1,1,3,3-tetramethyluronium hexafluorophos-
phate (HATU). The HYNIC-cRGD conjugate was
> 98%, chemically pure as analyzed by reversed
phase high-performance liquid chromatography
(HPLC, Waters instrument running Millenium soft-
ware with both radioactivity and UV photodiode ar-
ray in-line detectors).
The lyophilized kit was prepared with the HYNIC-
cRGD conjugate plus ethylendiaminodiacetic acid
(EDDA) and tricine as coligands and SnCl2 as a re-
ducing agent.
The radiopharmaceutical 99mTc-EDDA/HYNIC-cy-
clic-Arg-Gly-Asp-D-Phe-Lys (99mTc-cRGD) was pre-
pared by adding 99mTc-pertechnetate obtained from a
GETEC 99Mo/99mTc generator (ININ-Mexico) to the
lyophilized sterile kit and incubated for 15 min in
boiling water.25
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injected with the AR42J cells, 12 mice injected with
the MCF-7 cells and 12 mice injected with the PC-3
cells). Tumor growth was monitored frequently and
the length and width were measured in cm2 with cali-
pers. The final volume (cm3), after sacrifice, was ex-
pressed in grams.
In vivo biokinetics and cancer tumor uptake
When the tumors became visible (< 1 cm2) a mean of
18.5 MBq of the radiopeptide, was injected in a tail
vein (n = 3) for each time interval. After 0.5, 1, 3 and
24 h the mice were sacrificed in a CO2 chamber. The
tumor and the organs or tissues (blood, heart, lung,
liver, spleen, pancreas, kidneys, thigh muscle and fe-
mur) were excised, blotted dry and put into plastic test
tubes, previously weighed. The weight of the organ and
the anatomic characteristics of the tumors were record-
ed. Activity of the tumor and organs was measured in a
crystal scintillation [NaI (Tl)] well-type detector. The
mean of 3 diluted aliquots of the injected activity (I.A.)
were considered as the 100% uptake. Percentage up-
take or activity A (number of disintegrations per unit
time) of each organ or tissue was calculated and the re-
sults were expressed as the percentage of injected activi-
ty per gram of tissue (%IA/g). Tumor/blood and tumor/
muscle ratios were calculated. Each value represents
the mean and SD of three animals.
To evaluate the kinetics of the system a compart-
mental model was developed using the OLINDA/EXM
code. The program allows the user to enter kinetic
data and fit it to one or more exponential terms. The
total number of disintegrations (N), in source re-
gions, was calculated, integrated over time and ex-
pressed per unit of initial activity in the source re-
gion: MBq-h/MBq (previously considered as residence
time in the MIRD code) equation 1.27
(1)               dtAN
t
t
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



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Image acquisition
Imaging of mice injected with 99mTc-cRGD was per-
formed with a Siemens E-cam SPECT single head
gamma camera with a pinhole collimator.
Statistical strategy
The mean % uptake for each lot of 3 mice per time in-
terval was calculated. The statistical method em-
Evaluation of radiochemical purity
Radiochemical purity analyses were performed by so-
lid phase extraction (Sep-Pak C-18 cartridges), re-
verse phase high-performance liquid chromatography
(HPLC) and by instant thin-layer chromatography
on silica gel (ITLC-SG, Gelman Sciences) with three
different mobile phases: 2-butanone to determine the
amount of free 99mTcO4
- (Rf = 1); 0.1 M sodium ci-
trate pH 5 to determine 99mTc-EDDA coligand and
99mTcO4
- (Rf = 1) and, methanol: 1 M ammonium ace-
tate (1:1 v/v) for 99mTc-colloid (Rf = 0).25
Cancer cell lines
Three cancer producing cell lines were used:
a) The AR42J murine pancreatic cancer cell line
(ATTC, Rockville, MD, USA) over-expresses soma-
tostatin receptors (SS). The cells were routinely
cultivated at 37 °C in 5% CO2 and 85% air humidi-
fied atmosphere in Dulbecco’s minimum essential
culture medium (DMEM) (Life Technologies, Inc,
Gaithersburg, MD) which was supplemented with
5% fetal-bovine-serum and 100 U/mL of penicillin
and 100 g/mL streptomycin.
b) The MCF-7 cell line is derived from human breast
cancer and overexpresses cholecystokinin recep-
tors (CCK). The cells were cultivated in DMEM
and 10 nM estradiol and incubated in 5% CO2 at
37 °C, 85% atmosphere and humidity.
c) The PC-3 human prostate cancer cell line PC-3
was originally obtained from ATCC (USA) and
overexpresses gastrin releasing peptide receptors
(GRP). PC-3 cells were routinely grown in "RPMI"
culture medium supplemented with 10% newborn
calf serum and streptomycin (100 g/mL) at 37 °C,
with 5% CO2 atmosphere and 85% humidity.
26
Induced cancer tumors in athymic mice
Animal experiments were carried out in compliance
with the Official Mexican Norm (NOM 062-Zoo-
1999): rules and regulations for safe and adequate
laboratory animal handling.
Athymic adult male mice (20-22 g) were kept in
sterile cages with beds of sterile wood shavings, con-
stant temperature, humidity, noise and 12:12 light
periods. Water and feed (standard PMI 5001 feed)
were given ad libitum. The cancer cells (1 x 106 in
0.1 mL) were implanted in 36 athymic mice by sub-
cutaneous injection into the animal’s back (12 mice
Fred A. López-Durán y cols.
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ployed was the t-Student’s test for the activity of the
tumor vs. muscle for each time interval after admin-
istration. The significance level was p = 0.05.
RESULTS
The average radiochemical purity of 99mTc-cRGD was
> 95% in all cases. Free 99mTcO4 was < 2 %; 2-3% of
99mTc-EDDA and < 1.0% of 99mTc-colloid.
The biodistribution of 99mTc-cRGD in the three
models of induced cancer tumors are summarized in
table I. The radiopeptide shows favorable pharmaco-
kinetic properties such as rapid blood clearance and
renal elimination. Activity was accumulated mainly
in the liver, spleen and kidneys.
There was a high in vivo stability in the induced
tumors (pancreas, breast and prostate). Low muscle
uptake (background activity) was observed in all the
mice. Twenty four hours after radiopharmaceutical
administration the mean percentage of the injected
activity per gram of tissue (%IA/g) found in the mu-
rine pancreatic cancer tumor was 0.73 ± 0.36%
(AR42J cells); 1.31 ± 0.24% in breast cancer (MCF-7
cells) and 0.67 ± 0.02% in the prostatic cancer (PC-3
cells), (Table I). The anatomical characteristics for
the xenograft pancreatic tumor were of a large, fria-
ble hemorrhagic mass; the breast tumor was white,
compact and hard; the prostatic tumor was white
with a discreet beige coloring, compact and hard to
the touch. The tumor/blood ratios of % IA/g tissue in
24 h after administration were 14.6 for the AR42J
cell line; 10.9 for the MCF-7 cell line; 9.5 for the PC-
3 cell line. The tumor to muscle ratio after 24 h in
the pancreatic tumor induced with the AR42J cell
line was 4.0; in the hard, compact breast cancer
(MCF-7 cell line) was 7.2 and for the PC-3 cell line
(prostate) the ratio was 3.5 (Table II). The reason for
these differences might be that in the hemorrhagic
pancreatic tumor the activity leaks out, in the com-
pact dense breast tumor it remains inside the tumor
and in the poorly vascular prostatic tumor the activi-
ty is minor.
Table I. Biodistribution data for 99mTc-cRGD in an athymic mice model bearing induced tumors expressed as % injected activity /
gram of tissue (%IA/ g tissue), at different time intervals (0.5 to 24 h).
% IA /g tissue
Organ Time p.i. (h) AR42J (Pancreas) MCF-7 (Breast) PC-3 (Prostate)
Blood 0.5 3.15 ± 0.48 1.66 ± 0.21 0.88 ± 0.52
1 2.86 ± 0.38 0.68 ± 0.10 0.70 ± 0.10
3 0.31 ± 0.05 0.31 ± 0.02 0.34 ± 0.07
24 0.05 ± 0.03 0.12 ± 0.04 0.07 ± 0.01
Liver 0.5 2.14 ± 0.57 2.15 ± 0.24 2.14 ± 0.04
1 2.79 ± 0.47 1.60 ± 0.18 2.45 ± 0.43
3 2.31 ± 0.60 1.51 ± 0.13 1.57 ± 0.40
24 0.83 ± 0.31 0.91 ± 0.15 1.16 ± 0.47
Spleen 0.5 2.53 ± 0.03 1.72 ± 0.19 2.02 ± 0.37
1 1.09 ± 0.07 1.56 ± 0.65 2.11 ± 0.20
3 1.11 ± 0.19 1.42 ± 0.40 1.48 ± 0.28
24 0.53 ± 0.18 1.16 ± 0.21 1.89 ± 0.57
Kidneys 0.5 3.75 ± 0.74 4.04 ± 0.12 6.62 ± 0.79
1 9.75 ± 1.84 3.07 ± 0.01 3.02 ± 0.14
3 2.65 ± 0.41 3.02 ± 0.30 2.28 ± 0.36
24 1.37 ± 0.44 1.95 ± 0.04 1.53 ± 0.33
Muscle 0.5 0.90 ± 0.06 0.73 ± 0.14 0.65 ± 0.04
1 1.09 ± 0.14 0.46 ± 0.09 0.58 ± 0.06
3 0.33 ± 0.05 0.32 ± 0.02 0.34 ± 0.06
24 0.18 ± 0.03 0.18 ± 0.03 0.19 ± 0.05
Tumor 0.5 2.26 ± 0.24 2.00 ± 0.60 1.59 ± 0.27
1 2.84 ± 0.14 1.71 ± 0.52 1.48 ± 0.19
3 2.15 ± 0.15 1.61 ± 0.37 1.23 ± 0.29
24 0.73 ± 0.36 1.31 ± 0.24 0.67 ± 0.02
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There is a statistical difference (p < 0.05) in %
IA/g tumor vs muscle for the 3 tumors and for each
mean time interval (Table III).
Figure 1 shows 0.5-24 h uptake tumor data for
each cell line inductor. The optimal time for activity
concentration was observed between 1 h to 3 h for
the three cell lines. The total number of disintegra-
tions N in the source organs is shown in Table IV.
The back bearing induced human breast cancer
tumor showed the highest uptake (6.15%). A dorsal
SPECT image of one representative athymic mouse
3 h after injection is shown in figure 2.
DISCUSSION
For their growth cancer tumors require new blood
vessel formation via angiogenic factors and one of
these factors is the v 3 integrin. Besides alfa5 beta3
receptors the 3 tumors studied overexpress specific re-
ceptors: somatostatin in pancreatic cancer, cholecys-
tokinin (CCK) in breast cancer and gastrin releasing
peptide (GRP) in prostate cancer and the 3 tumors
showed different degrees of radiopharmaceutical up-
take which might be due to the differences in vascula-
ture and to the amount of integrins present in the
blood vessels regardless of other specific receptors.
As mentioned above, angiogenesis is a complex
natural physiologic process that refers to the remo-
deling of the vascular tissue and it is characterized by
the branching out of new blood vessels from preexist-
ing vessels. Pathologic angiogenesis is found in can-
cer tumors and in several other pathologic entities.
Angiogenesis can be imaged because of integrin tar-
geting and uptake of radiopharmaceuticals. Early at-
tempts using direct 99mTc labeling approaches were
reported without showing specific in vivo uptake.28,29
Other groups of researchers have reported indirect
99mTc labeling using HYNIC conjugated to peptide
analogues.
Janssen et al. have compared the tumor targeting
characteristics of a monomeric radiolabelled RGD-
peptide with those of a dimeric analogue.3 Both pep-
tides were radiolabelled with 99mTc via HYNIC to
form 99mTc-HYNIC-c(RGDfK) and 99mTc-HYNIC-
E[c(RGDfK)]2. In vitro, the IC50 showed a 10-fold
higher affinity of the dimer as compared to the mono-
mer (0.1 vs. 1.0 nM). In athymic female BALB/c mice
with subcutaneously growing OVCAR-3 ovarian car-
Table II. Tumor-to-organ ratios in an athymic mice model
bearing induced tumors at different time intervals (0.5 to 24 h).
Time p.i. AR42J MCF-7 PC-3
(h) (Pancreas) (Breast) (Prostate)
Tumor/blood 0.5 0.71 1.20 1.80
1 0.99 2.51 2.11
3 6.93 5.19 3.61
24 14.6 10.91 9.57
Tumor /muscle 0.5 2.51 2.73 2.44
1 2.60 3.71 2.55
3 6.51 5.03 3.61
24 4.05 7.27 3.52
Table III. Statistical analysis of the tumor activity vs muscle activity for each induced tumor per time intervals (t-Student’s
test) n = 3 for each time.
AR42J %IA/g tissue
0.5 h 1 h 3h 24 h
Muscle Tumor Muscle Tumor Muscle Tumor Muscle Tumor
Mean 0.93 2.43 1.08 2.84 0.32 2.15 0.17 0.73
Variance 0.003 0.092 0.045 0.039 0.006 0.045 0.001 0.171
t = 8.40 t = 8.58 t = 11.42 t = 2.66
p = 0.001 p = 0.013 p = 0.008 p = 0.037
MCF7
Mean 0.73 2.00 0.46 1.71 0.32 1.61 0.18 1.31
Variance 0.031 0.543 0.011 0.400 6.11E-4 0.201 4.0E-4 0.090
t = 2.90 t = 3.36 t = 4.97 t = 6.47
p = 0.044 p = 0.028 p = 0.007 p = 0.003
PC3
Mean 0.65 1.59 0.58 1.48 0.34 1.23 0.19 0.67
Variance 0.002 0.151 0.006 0.054 0.005 0.127 0.004 0.001
t = 4.57 t = 6.32 t = 4.25 t = 9.83
p = 0.019 p = 0.003 p = 0.013 p = 0.002
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cinoma xenografts, the dimeric RGD peptide showed
better retention in the tumor than the monomeric an-
alogue, most likely due to the bivalent interaction
with the target cell.
The cyclic HYNIC-derivatized monomeric RGD
peptide [c(RGDyK(HYNIC)] was successfully 99mTc
labeled using EDDA and tricine as coligands.24
Evaluation of radiolabeling of linear and cyclic
RGD peptides was determined using a carbonil pre-
cursor [99mTc(H2O)3(CO)3]
+ and the uptake of the
Figure 2. A selected image of an athymic mouse with induced
tumor of human breast cancer 3 h after injection of 99mTc-
cRGD was taken after dissection of internal viscera to highlight
the tumor uptake (tumor/muscle ratio 6.15),
Tumor,
uptake
Table IV. Total number of disintegrations (N) in the source
organs of athymic mice with induced cancer tumors expressed
per unit activity administered, (OLINDA/EXM).
Total number of disintegrations (N) MBq-h/MBq
Induced cancer tumor
Organ Pancreas Breast Prostate
Blood 0.061 0.040 0.030
Heart 0.030 0.037 0.031
Lung 0.074 0.061 0.057
Liver 0.181 0.193 0.015
Spleen 0.143 0.154 0.154
Pancreas 0.038 0.043 0.030
Kidneys 0.279 0.342 0.251
Intestine 0.211 0.255 0.244
Muscle 0.024 0.029 0.027
Bone 0.016 0.058 0.034
Tumor 0.140 0.126 0.096
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Figure 1. Biokinetics of 99mTc-cRGD in cancer tumors induced
with cell lines a) AR42J (murine pancreas cancer); b) MCF-7 (hu-
man breast cancer) and c) PC-3 (human prostate) in 0.5 to 24 h.
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ESTE DOCUMENTO ES ELABORADO POR MEDIGRAPHIC
cRGDfK-His was higher than that with the linear
peptide.30
99mTc-RGD has been used in many studies as a
dimer or as a trimeric, tetrameric, octameric and
multimeric molecules for imaging of tumor integrin
v 3 expression, with good tumor uptake and favor-
able pharmacokinetics However all these peptides
need to be synthetized.3,11,14,31
We used the commercial cyclic pentapeptide con-
taining a phenylalanine amino acid (cyclic-Arg-Gly-
Asp-D-Phe-Lys) which was conjugated with HYNIC
and EDDA and tricine as coligands to form 99mTc-
EDDA/HYNIC-cyclic-Arg-Gly-Asp-D-Phe-Lys
(99mTc-cRGD).
Our research has led us to conclude that a highly
stable, radiochemically pure, freeze dried kit can be
99mTc radio labeled in any hospital radiopharmacy.
The 99mTc-cRGD targets v 3 integrin receptors in
cancer tumor angiogenesis and allows noninvasive
imaging of malignant tumors in a murine model.
This could be a promising radiopharmaceutical for
imaging cancer tumor angiogenesis in human beings.
The advantage of this lyophilized formulation of
the cRGD peptide conjugated to HYNIC and with the
added coligands EDDA and tricine over other report-
ed formulations is that cRGD kit is easily labeled in
one step with technetium-99m in any hospital radio-
pharmacy. The radiopharmaceutical 99mTc-cRGD tar-
geted v 3 integrin receptors in athymic mice with 3
xenografted pancreas, breast and prostate cancer tu-
mors and the tumor to muscle ratio are high allow-
ing a better resolution of the tumor uptake over the
muscle background in the SPECT image.
This non invasive nuclear medicine procedure de-
monstrated that 99mTc-cRGD will be of great value as a
radiopharmaceutical for v 3 integrin receptor uptake
and for imaging angiogenesis in neoplastic tissue.
ACKNOWLEDGMENTS
This study was supported by the CONACyT-Mexico
52633-M project.
Our gratitude to Jesús Sepúlveda-Méndez MD;
Ma. Minerva Méndez-Fernández NMT; Ma. Guada-
lupe Soto-Gutiérrez NMT; Manuel Maury-Ruiz
NMT; Armando Jiménez-Yedra NMT for obtaing
the mice images.
REFERENCES
1. Carmeliet P, Jain RK. Angiogenesis in cancer and other
diseases. Nature. 2000; 407: 249-57.
2. Haubner R. v 3-integrin imaging: a new approach to
characterize angiogenesis? Eur J Nucl Med Mol Imaging.
2006; 33: 54-63.
3. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I,
Edwards DS, et al. Comparison of a monomeric and dimer-
ic radiolabeled RGD-peptide for tumor targeting. Cancer
Biother Radiopharm. 2002; 17: 641-6.
4. Line BR, Mitra A, Nan A, Ghandehari H. Targeting tumor
angiogenesis: Comparison of peptide and polymer-peptide
conjugates. J Nucl Med. 2005; 40: 1552-60.
5. Felding-Habermann B, Mueller BM, Romerdahl CA,
Cheresh DA. Involvement of integrin alphaV gene expres-
sion in human melanoma tumourigenicity. J Clin Invest.
1992; 89: 2018-22.
6. D’Andrea LD, Del Gatto A, Pedone C, Benedetti E. Peptide-
based molecules in angiogenesis. Chem Biol Drug Des.
2006; 67: 115-26.
7. Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Asgeirsdóttir SA,
Everts M, et al. Preparation and functional evaluation of
RGD-modified proteins as alpha(v)beta(3) integrin directed
therapeutics. Bioconjug Chem. 2002; 13: 128-35.
8. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidt-
ke R, Diefenbach B, Kessler H, et al. Radiolabeled
alpha(v)beta3 integrin antagonists: A new class of tracers
for tumor targeting. J Nucl Med. 1999; 40: 1061-71.
9. Haubner R, Wester HJ. Radiolabed tracers for imaging of
tumour angiogenesis and evaluation of anti-angiogenic
therapies. Curr Pharm Des. 2004; 10: 1439-55.
10. Yoshimoto M, Ogawa K, Washiyama K, Shikano N, Mori H,
Amano R, et al. Alpha(v)beta(3) Integrin-targeting radio-
nuclide therapy and imaging with monomeric RGD pep-
tide. Int J Cancer. 2008; 123: 709-15.
11. Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD
peptides for microPET imaging of integrin alpha(v)beta
(3) expression. Eur J Nucl Med Mol Imaging. 2008; 35:
1100-8.
12. Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon
GJ, et al. Preparation of a promising angiogenesis PET im-
aging agent: 68Ga-labeled c(RGDyK)-isothiocyanatoben-
zyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibil-
ity studies in mice. J Nucl Med. 2008; 49: 830-6.
13. Knight LC. In handbook of radiopharmaceuticals; Welch
MJ, and Redvanly CS, eds. England: John Wiley & Sons;
2003. p. 643-84.
14. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. 64Cu-La-
beled tetrameric and octameric RGD peptides for small-ani-
mal PET of tumor v 3 integrin expression. J Nucl Med.
2007; 48: 1162-71
15. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sar-
bia M, et al. Noninvasive visualization of the activated v 3
integrin in cancer patients by positron emission tomogra-
phy and [18F]galacto-RGD. PLoS Med. 2005; 2: 29.
16. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et
al. Quantitative PET imaging of tumor integrin v 3 ex-
pression with 18F-FRGD2. J Nucl Med. 2006; 47: 113-21.
17. Li ZB, Wu Z, Chen K, Ryu EK, Chen X. 18F-labeled BBN-
RGD heterodimer for prostate cancer imaging. J Nucl
Med. 2008; 49: 453-61.
18. Glaser M, Morrison M, Solbakken M, Arukwe J, Karlsen H,
Wiggen U, et al. Radiosynthesis and biodistribution of cy-
clic RGD peptides conjugated with novel [18F]fluorinated
aldehyde-containing prosthetic groups. Bioconjug Chem.
2008; 19: 951-7.
19. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT, et al. Micro-
PET of tumor integrin alpha-beta3 expression using 18F-
Fred A. López-Durán y cols.
68 Bioquimia
labeled PEGylated tetrameric RGD peptide (18F-FPRGD4).
J Nucl Med. 2007; 48: 1536-44.
20. Liu S, Edwards DS. 99mTc-Labeled small peptides as di-
agnostic radiopharmaceuticals. Chem Rev. 1999; 99:
2235-68.
21. Bock M, Bruchertseifer F, Haubner R, Senekowitsch-
Schmidtke R, Kessler H, Schwaiger M, et al. Tc-99m-, Re-
188- and Y-90-labeled v 3 antagonists: promising tracer
for tumor-induced angiogenesis. J Nucl Med. 2000; 41:
41P.
22. Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich
DJ. In vitro and in vivo evaluation of a technetium-99m-
Labeled cyclic RGD peptide as a specific marker of v 3 in-
tegrin for tumor imaging. Bioconjugate Chem. 2002; 13:
561-70.
23. Liu S, Hsieh WY, Kim YS, Mohammed SI. Effect of coli-
gands on biodistribution characteristics of ternary ligand
99mTc complexes of a HYNIC-conjugated cyclic RGDfK
dimer. Bioconjugate Chem. 2005; 16: 1580-8.
24. Decristoforo C, Faintuch-Linkowski B, Rey A, von
Guggenberg E, Rupprich M, Hernandez-Gonzales I, et al.
[99mTc]HYNIC-RGD for imagin integrin v 3 expression.
Nucl Med Biol. 2006; 33: 945-52.
25. Ferro-Flores G, Arteaga de Murphy C, Rodríguez-Cortés J,
Pedraza-López M, Ramírez-Iglesias T. Preparation and
evaluation of 99mTc-EDDA/HYNIC-[Lys3]-Bombesin for
imaging of gastrin-releasing peptide receptor-positive tu-
mours. Nucl Med Commun. 2006; 27: 371-6.
26. Larrea F, García-Becerra R, Lemus AE, García GA, Pérez-
Palacios G, Jackson KJ, et al. A-ring reduced metabolites
of 19-nor synthetic progestins as subtype selective agonists
for ERa. Endocrinology. 2001; 142: 3791-9.
27. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The sec-
ond-generation personal computer software for internal
dose assessment in nuclear medicine. J Nucl Med. 2005;
46: 1023-7.
28. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E,
Milonakis A, Sirmalis G, et al. Related imaging of metasta-
tic melanoma utilizing a technetium-99m labelled RGD-
containing synthetic pepetide. Eur J Nucl Med. 1998; 25:
1383-9.
29. Noiri E, Goligorsky MS, Wang GJ, Wang J, Cabahug CJ,
Sharma S, et al. Biodistribution and clearance of 99mTc-
labeled Arg-Gly-Asp(RGD) peptide in rats with ischemic
acute renal failure. J Am Soc Nephrol. 1996; 7: 2682-8.
30. Fani M, Psimadas D, Zikos C, Xanthopoulos S, Loudos
GK, Bouziotis P, et al. Comparative evaluation of linear
and cyclic 99mTc-RGD peptides for targeting of integrins
in tumor angiogenesis. Anticancer Res. 2006; 26: 431-4.
31. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, et al.
Integrin v 3-Targeted Imaging of Lung Cancer. Neopla-
sia. 2005; 7: 271-9.
